Shots: Guidelines for Kidney Cancer: CABOMETYX (TKi) is recommended for 1L RCC patients in the poor- and intermediate-risk groups (Category 2A), 1L treatment for favourable-risk patients (Category 2B), and for previously treated patients (Category 1) The (Category 2A) guidelines are based on P-II CABOSUN trial (N=157) in (ratio 1:1) administering cabozantinib (60mg qw)/sunitinib (50mg qw,4 […]Read More
Tags : clinical practice guidelines
Latest Posts
Categories
Related Topics
AbbVie
Acquire
Adults
Agreement
Amgen
approval
AstraZeneca
Bayer
Biosimilar
BMS
Collaborates
Collaboration
Commercialize
COVID-19
Develop
Development
Eli Lilly
EU
Exclusive
FDA
Gilead
GSK
Janssen
Launches
License
License Agreement
Merck
Novartis
P-III
patients
Pfizer
receives
Regeneron
Report
reports
results
Roche
Sanofi
Signs
study
Takeda
the US FDA
Treat
Treatment
US